<DOC>
	<DOCNO>NCT00807859</DOCNO>
	<brief_summary>The purpose study determine AMG 386 combination either paclitaxel trastuzumab capecitabine lapatinib safe well tolerated subject HER2-positive locally recurrent metastatic breast cancer . This open-label phase 1b trial 2 study part . Study part 1 dose escalation study determine tolerable dose AMG 386 combination paclitaxel trastuzumab ( cohort A ) capecitabine lapatinib ( cohort B ) . Study part 2 cohort expansion tolerable dos determine part 1 .</brief_summary>
	<brief_title>Safety Study AMG 386 Treat HER2-positive Locally Recurrent Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Neoplasm Metastasis</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Trebananib</mesh_term>
	<mesh_term>Lapatinib</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>histologically cytologically confirm adenocarcinoma breast locally recurrent metastatic disease amenable local treatment curative intent . HER2positive FISH , CISH , IHC 3+ ECOG performance status 0 1 Left ventricular ejection fraction great equal institutional low limit normal Adequate laboratory study ( hematological , chemistry urinalysis ) Life expectancy great equal 3 month Cohort A : Trastuzumab naïve trastuzumab neoadjuvant set No clinically significant drop cardiac function prior exposure trastuzumab No prior chemotherapy metastatic locally recurrent breast cancer No prior lapatinib therapy At least 3 week enrollment since prior chemotherapeutic agent , include taxanes , neoadjuvant adjuvant setting At least 3 month enrollment since prior trastuzumab neoadjuvant adjuvant set Cohort B : Must fail trastuzumab firstline metastatic setting . Trastuzumab must discontinue least 3 week prior enrollment Must receive prior chemotherapy adjuvant therapy metastatic disease Prior chemotherapy treatment must discontinue least 3 week prior enrollment No prior capecitabine No prior lapatinib Inflammatory breast cancer Central nervous system metastasis Clinically significant cardiovascular disease Radiation therapy ≤ 14 day prior enrollment . Concurrent anticoagulation therapy , exclude aspirin , antiplatelet agent , low molecular weight heparin low dose warfarin per protocol . Uncontrolled hypertension define diastolic blood pressure &gt; 90 mmHg OR systolic blood pressure &gt; 140 mmHg . Subjects history prior malignancy , except : For Cohort B : Current prior history long QT syndrome Baseline ECG report QTc interval &gt; 480 millisecond Severe chronic liver disease ( Child Pugh C )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>AMG 386</keyword>
	<keyword>Paclitaxel</keyword>
	<keyword>Trastuzumab</keyword>
	<keyword>Capecitabine</keyword>
	<keyword>Lapatinib</keyword>
	<keyword>HER2-positive</keyword>
	<keyword>metastatic breast cancer</keyword>
	<keyword>locally recurrent breast cancer</keyword>
	<keyword>Taxol</keyword>
	<keyword>Herceptin</keyword>
	<keyword>Xeloda</keyword>
	<keyword>Tykerb</keyword>
	<keyword>anti-angiogenic therapy</keyword>
</DOC>